PLCG1
PLCG1 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Renal cell carcinoma, Non-Hodgkin lymphoma and 5 more.
Overview
Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signalling cascades. Becomes activated in response to ligand-mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, EGFR, FGFR1, FGFR2, FGFR3 and FGFR4.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes literature 0.95, affected pathway 0.97, genetic association 0.17, somatic mutation 0.91). IntOGen calls it a driver in 4 cohorts (4 activating, 0 loss-of-function), covering Angiosarcoma, Low-Grade Glioma, NOS, Renal Cell Carcinoma, Soft Tissue.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PLCG1 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Renal cell carcinoma, Non-Hodgkin lymphoma and 5 more.
- 1 · What it is
PLCG1 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Renal cell carcinoma, Non-Hodgkin lymphoma and 5 more.
- 2 · What goes wrong in cancer
Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signalling cascades.
- 3 · How drugs use it
No product in this corpus aims at PLCG1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:9065 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P19174 (protein name, function text, keywords and locations (REST API)); CIViC gene PLCG1 (1 evidence items, 0 assertions, 1 variants; diseases: Adult T-cell Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000124181 (association with cancer (MONDO_0004992) 0.79; per-cancer scores at or above 0.5: gastric cancer 0.50, melanoma 0.52, sarcoma 0.58, non-Hodgkin lymphoma 0.56, skin cancer 0.55, leukaemia 0.52 (GraphQL API, CC0)); IntOGen PLCG1 (driver in 4 cohorts (Act 4, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signalling cascades. Becomes activated in response to ligand-mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, EGFR, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in actin reorganisation and cell migration. Guanine nucleotide exchange factor that binds the GTPase DNM1 and catalyses the dissociation of GDP, allowing a GTP molecule to bind in its place, therefore enhancing DNM1-dependent endocytosis. Location: Cell projection, lamellipodium; Cell projection, ruffle (UniProt). Locus 20q12 (HGNC).
- Sarcomas: Open Targets association 0.58 with sarcoma (MONDO_0005089); IntOGen driver in 1 cohort (SOFT_TISSUE)
- Renal cell carcinoma: IntOGen driver in 1 cohort (RCC)
- Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Leukaemia: Open Targets association 0.52 with leukaemia (MONDO_0005059)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.50 with gastric cancer (MONDO_0001056)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Adult T-cell Leukaemia/lymphoma; Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"PLCG1" OR ABSTRACT:"PLCG1" OR TITLE:"phospholipase C gamma 1" OR ABSTRACT:"phospholipase C gamma 1" OR TITLE:"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1" OR ABSTRACT:"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1" OR TITLE:"PLC148" OR ABSTRACT:"PLC148" OR TITLE:"PLC-II" OR ABSTRACT:"PLC-II" OR TITLE:"PLCgamma1" OR ABSTRACT:"PLCgamma1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PLCG1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPOT1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetERG
Shares Angiosarcoma, Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetPRF1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Gastric & gastro-oesophageal junction cancer.
- TargetPTPRB
Shares Angiosarcoma, Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetIL2RG
Shares Leukaemia (all types), Skin cancer (all types), Renal cell carcinoma, Non-Hodgkin lymphoma (all types).
- TargetPIK3R1
Shares Leukaemia (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetIL7R
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetNFKBIE
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.